Dany Jaffuel, Erika Nogue, Philippe Berdague, Michel Galinier, Pauline Fournier, Marion Dupuis, Frédéric Georger, Marie-Pierre Cadars, Jean-Etienne Ricci, Nathalie Plouvier, François Picard, Vincent Puel, Jean-Pierre Mallet, Carey M Suehs, Nicolas Molinari, Arnaud Bourdin, François Roubille
AIMS: Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril-valsartan (SV), a cornerstone of HFrEF medical treatment, impacts SA is unknown and requires evaluation. METHODS AND RESULTS: The ENTRESTO-SAS trial is a six-centre, prospective, open-label real-life cohort study (NCT02916160)...
August 2021: ESC Heart Failure